LVAMX
Price
$10.94
Change
+$0.06 (+0.55%)
Updated
Jun 2 closing price
Net Assets
27.48M
RWMHX
Price
$68.64
Change
+$0.27 (+0.39%)
Updated
Jun 2 closing price
Net Assets
214.46B
Interact to see
Advertisement

LVAMX vs RWMHX

Header iconLVAMX vs RWMHX Comparison
Open Charts LVAMX vs RWMHXBanner chart's image
LVAMX vs RWMHX Comparison Chart in %
View a ticker or compare two or three
VS
LVAMX vs. RWMHX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LVAMX is a Buy and RWMHX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RWMHX has more cash in the bank: 214B vs. LVAMX (27.5M). LVAMX pays higher dividends than RWMHX: LVAMX (1.44) vs RWMHX (1.32). LVAMX was incepted earlier than RWMHX: LVAMX (12 years) vs RWMHX (11 years). LVAMX (1.22) is less costly to investors than RWMHX (0.41). LVAMX (30.00) and RWMHX (29.00) have comparable annual turnover. RWMHX has a lower initial minimum investment than LVAMX: RWMHX (250) vs LVAMX (1000). RWMHX annual gain was more profitable for investors over the last year : 7.97 vs. LVAMX (1.86). RWMHX return over 5 years is better than : 26.14 vs. LVAMX (-9.98).
LVAMXRWMHXLVAMX / RWMHX
Total Expense Ratio0.800.41195%
Annual Report Gross Expense Ratio1.220.41298%
Fund Existence12 years11 years-
Gain YTD11.7045.528212%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets27.5M214B0%
Annual Yield % from dividends1.441.32109%
Returns for 1 year1.867.9723%
Returns for 3 years2.0732.666%
Returns for 5 years-9.9826.14-38%
Returns for 10 years19.4384.3223%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JVASX38.87N/A
N/A
JPMorgan Value Advantage I
RTSAX46.98N/A
N/A
Russell Inv Tax-Managed US Mid&Sm Cap A
ETHSX12.26N/A
N/A
Eaton Vance Worldwide Health Sci A
GVCAX12.36N/A
N/A
Gabelli Value 25 AAA
MDOEX12.67N/A
N/A
Morgan Stanley Developing Opportunity I